CN111372598A - 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 - Google Patents

使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 Download PDF

Info

Publication number
CN111372598A
CN111372598A CN201880063962.8A CN201880063962A CN111372598A CN 111372598 A CN111372598 A CN 111372598A CN 201880063962 A CN201880063962 A CN 201880063962A CN 111372598 A CN111372598 A CN 111372598A
Authority
CN
China
Prior art keywords
eye
condition
cells
disease
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063962.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍普金斯
P·苏鲁达
C·查普曼
H·斯威加德
Y·潘
D·马克斯
N·大卫
J·达南伯格
R-M·雷伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barker Institute Of Aging
United Biotechnology
Original Assignee
Barker Institute Of Aging
United Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/675,171 external-priority patent/US20180000816A1/en
Application filed by Barker Institute Of Aging, United Biotechnology filed Critical Barker Institute Of Aging
Publication of CN111372598A publication Critical patent/CN111372598A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880063962.8A 2017-08-11 2018-08-13 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况 Pending CN111372598A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/675,171 2017-08-11
US15/675,171 US20180000816A1 (en) 2015-02-06 2017-08-11 Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US201762579793P 2017-10-31 2017-10-31
US62/579,793 2017-10-31
PCT/US2018/046553 WO2019033119A1 (en) 2017-08-11 2018-08-13 TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS

Publications (1)

Publication Number Publication Date
CN111372598A true CN111372598A (zh) 2020-07-03

Family

ID=63254539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063962.8A Pending CN111372598A (zh) 2017-08-11 2018-08-13 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况

Country Status (7)

Country Link
EP (2) EP3441069B1 (https=)
JP (2) JP7278257B2 (https=)
CN (1) CN111372598A (https=)
AU (2) AU2018314280B2 (https=)
CA (1) CA3072673A1 (https=)
MX (2) MX2020001644A (https=)
WO (1) WO2019033119A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115568281A (zh) * 2021-05-04 2023-01-03 福森生物科技有限公司 一种含有咪唑啉衍生物化合物作为有效成分的用于治疗黄斑变性的药物组合物
WO2024051741A1 (zh) * 2022-09-06 2024-03-14 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
JP7080346B2 (ja) 2018-04-30 2022-06-03 ユニティ バイオテクノロジー インコーポレイテッド 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CA3109432A1 (en) * 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
JP2022548071A (ja) * 2019-09-13 2022-11-16 アメリカ合衆国 網膜変性を治療するための新薬の開発につながる標的
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
JP2024516367A (ja) * 2021-04-13 2024-04-15 ユニティ バイオテクノロジー インコーポレイテッド 網膜血管症を治療する方法
DE112024002866T5 (de) * 2023-07-06 2026-04-23 Jichi Medical University Konzentrationsregulator für In-vivo-Substanzen oder Medikamente in einem halbgeschlossenen In-vivo-System
CN119925379B (zh) * 2025-03-05 2025-09-05 中南大学湘雅医院 Bcl3抑制剂在制备治疗青光眼的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103059A2 (en) * 2011-01-25 2012-08-02 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2014113413A1 (en) * 2013-01-16 2014-07-24 The Regents Of The University Of Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
BR0208856B1 (pt) 2001-04-11 2013-02-05 processo para o tratamento de superfÍcie de uma junta com rosca e junta com rosca para tubos de aÇo.
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
WO2009094466A2 (en) 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Contact lenses for extended release of bioactive agents containing diffusion attenuators
US8353856B2 (en) 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
CN105377289A (zh) * 2013-04-21 2016-03-02 耶达研究及发展有限公司 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂
US20150038140A1 (en) 2013-07-31 2015-02-05 Qualcomm Incorporated Predictive mobility in cellular networks
WO2015017536A1 (en) 2013-07-31 2015-02-05 The Board Of Trustees Of The Leland Stanford Junior University Method and system for evaluating progression of age-related macular degeneration
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2017008060A1 (en) * 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US11111259B2 (en) * 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103059A2 (en) * 2011-01-25 2012-08-02 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2014113413A1 (en) * 2013-01-16 2014-07-24 The Regents Of The University Of Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115568281A (zh) * 2021-05-04 2023-01-03 福森生物科技有限公司 一种含有咪唑啉衍生物化合物作为有效成分的用于治疗黄斑变性的药物组合物
WO2024051741A1 (zh) * 2022-09-06 2024-03-14 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用

Also Published As

Publication number Publication date
MX2025004366A (es) 2025-05-02
EP3441069A1 (en) 2019-02-13
JP2023100864A (ja) 2023-07-19
MX2020001644A (es) 2020-07-13
WO2019033119A1 (en) 2019-02-14
AU2018314280B2 (en) 2023-07-20
AU2023251388A1 (en) 2023-11-02
AU2018314280A1 (en) 2020-02-27
EP4234025A3 (en) 2024-04-24
RU2020109987A (ru) 2021-09-13
JP2020530470A (ja) 2020-10-22
EP3441069B1 (en) 2023-04-05
JP7278257B2 (ja) 2023-05-19
EP4234025A2 (en) 2023-08-30
CA3072673A1 (en) 2019-02-14
AU2023251388B2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
Scuderi et al. Pigment dispersion syndrome and pigmentary glaucoma: a review and update
De Keyser et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients
Davids et al. Ab interno canaloplasty (ABiC)—12-month results of a new minimally invasive glaucoma surgery (MIGS)
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
TW201440774A (zh) 眼底疾患治療劑
Hu et al. Efficacy of the XEN gel stent on intraocular pressure lowering in East Asian eyes
Li et al. Lacrimal duct occlusion is associated with infectious keratitis
Wood et al. Rare corneal complication following selective laser trabeculoplasty
Galloway et al. The Ageing Eye
RU2815482C2 (ru) Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки
HK40032714A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs
Dikmetas et al. Glaucoma and ocular surface
ALBÉ et al. Ocular diseases of importance to the refractive surgeon
Vallabh et al. Pathology of Glaucoma
Ji et al. Long-term Efficacy of Compound Trabeculectomy in the Treatment of Uveitic Glaucoma: A Retrospective Cohort Study
Jeganathan et al. Challenges in the management of glaucoma in a patient with severe ocular surface disease: a case report
Patel Development and Evaluation of a Nanomicellar Eye Drop Formulation of Dexamethasone for Posterior Uveitis
EL-Kasaby Internal Limiting Membrane Peeling for Diffuse Tractional Diabetic Macular Oedema
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Singla et al. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in preventing recurrence in primary pterygium excision
Arthurs et al. ANNUAL INDEX'INDEX ANNUEL

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032714

Country of ref document: HK